Stock Events

Stock Events

Cel-Sci 

0
68
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Sep 1996
€1,422.75
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

Dec 23Expected
Q1 2026
Q2 2026
Next
-0.57
-0.52
-0.46
-0.41
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-22.91MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow LSRM.STU. It's not an investment recommendation.
Apple
11
AAPL
Bitcoin
10
BTC.CRYPTO
AMD
10
AMD
Amazon
9
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Merck
MRK
Mkt Cap368.89B
Merck & Co. is a leading pharmaceutical company that competes with Cel-Sci in the immunotherapy and cancer treatment space, particularly with their blockbuster cancer drug Keytruda.
Bristol-Myers Squibb
BMY
Mkt Cap127.71B
Bristol-Myers Squibb competes in the oncology and immunotherapy sectors, offering products that directly compete with Cel-Sci's Multikine treatment.
Pfizer
PFE
Mkt Cap173.95B
Pfizer is a global pharmaceutical company with a broad portfolio that includes oncology products, competing in the same market as Cel-Sci.
Gilead Sciences
GILD
Mkt Cap211.7B
Gilead Sciences is involved in the development of immunotherapy treatments for cancer, making it a direct competitor to Cel-Sci.
Novartis
NVS
Mkt Cap303.67B
Novartis AG competes with Cel-Sci in the cancer immunotherapy field, with a strong focus on research and development in this area.
AMGEN
AMGN
Mkt Cap251.94B
Amgen is a biotechnology company with a focus on cancer treatments and immunotherapies, competing in the same space as Cel-Sci.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG, through its pharmaceuticals division, develops cancer immunotherapies, directly competing with Cel-Sci's product offerings.
Astrazeneca
AZN
Mkt Cap289.48B
AstraZeneca is involved in the development and commercialization of oncology and immunotherapy treatments, making it a competitor to Cel-Sci.
Regeneron Pharmaceuticals
REGN
Mkt Cap95.99B
Regeneron Pharmaceuticals is known for its innovative treatments in oncology, directly competing with Cel-Sci in the immunotherapy market.
Incyte
INCY
Mkt Cap24.54B
Incyte Corporation focuses on the discovery, development, and commercialization of cancer treatments, including immunotherapies, competing with Cel-Sci.

About

CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.
Show More
CEO
Geert R. Kersten
Employees
44
Country
United States
ISIN
US1508376076
WKN
000A418TV

Listings

STU
DE
LSR.STU
BOATS
BOATS
CVM.BOATS
F
DE
LSR.F
MU
DE
LSR.MU

0 Comments

Share your thoughts

FAQs

What is Cel-Sci stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Cel-Sci stocks are traded under the ticker LSRM.STU.
When is the next Cel-Sci earnings date?▼
Cel-Sci is going to release the next earnings report on December 23, 2026.
What were Cel-Sci earnings last quarter?▼
LSRM.STU earnings for the last quarter are -0.41 EUR per share, whereas the estimation was N/A EUR resulting in a N/A surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Cel-Sci revenue for the last year?▼
Cel-Sci revenue for the last year amounts to 0 EUR.
What is Cel-Sci net income for the last year?▼
LSRM.STU net income for the last year is -22.91M EUR.
Does Cel-Sci pay dividends?▼
Yes, LSRM.STU dividends are paid annual. The last dividend per share was 1,422.75 . As of today, Dividend Yield (FWD)% is 0%.
How many employees does Cel-Sci have?▼
As of November 7, 2026, the company has 44 employees.
In which sector is Cel-Sci located?▼
Cel-Sci operates in the Health & Wellness sector.
When did Cel-Sci complete a stock split?▼
The last stock split for Cel-Sci was on May 20, 2025 with a ratio of 1:30.
Where is Cel-Sci headquartered?▼
Cel-Sci is headquartered in VIENNA, United States.